July 4, 2023

Xigduo XR approved in China for adults with type-2 diabetes – AstraZeneca

AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycaemic control. Xigduo XR combines two anti-hyperglycaemic agents with complementary mechanisms of action: dapagliflozin (trade name, Forxiga), a sodium-glucose cotransporter […]

admin Health 0 1 min read
June 18, 2023

Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis – AstraZeneca

Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement inhibitor approved for the treatment of gMG in China. The approval by the National Medical Products Administration (NMPA) in China was based on comprehensive results from the Phase […]

admin Health 0 1 min read
March 2, 2022

Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus – AstraZeneca

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in Europe with an indication that is not restricted to patients with a high degree of disease activity. […]

admin Health 0 1 min read
September 28, 2021

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer – AstraZeneca + Daiichi Sankyo

Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients. DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based regimens. Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial […]

admin Health 0 3 min read
September 27, 2021

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN phase III trial in extensive-stage small cell lung cancer – AstraZeneca

Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting. These data, which show the longest survival update ever […]

admin Health 0 1 min read
June 9, 2021

Long-term data from PACIFIC phase III trial at ASCO showed 33% of NSCLC patients remained progression-free at five years – AstraZeneca

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read
May 10, 2021

Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated Joint Committee on Vaccination and Immunisation (UK) statement

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read
May 3, 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes – AstraZeneca

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read
April 19, 2021

Hypothesis for rare side effect linked to AstraZeneca vaccine

A hypothesis has been put forward as to why COVID-19 Vaccine AstraZeneca (ChAdOx1 nCov-19) seems to trigger an abnormal and potentially life-threatening combination of blood clotting and low platelet counts.Two research teams, each studying separate groups of patients came to similar conclusions. They both suggest the development of serious blood clots alongside falling levels of platelets — the sticky cells […]

admin Health 0 1 min read
April 9, 2021

AZD 1222 US phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis – AstraZeneca

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read

Recent Posts

Meta

Categories

Archives

Recent Comments